KEY DETAILS
New data on orforglipron show the pill's weight loss results hold steady across perimenopause and postmenopause, a stage most obesity drug trials leave out.
A doctor has flagged potential interactions between GLP-1 medications and cannabis, a detail worth discussing with your prescriber if it applies to you.
Eli Lilly has won FDA approval for a once weekly insulin, and the company's stock is approaching the $1,200 mark.
Viking Therapeutics reported strong VK2735 trial results, though the source urges some caution before reading too much into them.
WADA, which has monitored GLP-1s since 2024, declined to ban them this month and is funding a study on whether they boost performance.
New data on orforglipron, Eli Lilly's weight loss pill, show its results hold steady across perimenopause and postmenopause, a stage most obesity trials leave out entirely. That finding lands the same week Lilly picked up FDA approval for a once weekly insulin and watched its stock climb toward $1,200. Viking Therapeutics posted strong results for its own drug candidate, VK2735, though not without a caution attached. And WADA, which has monitored GLP-1s since 2024, declined to ban them this month and is funding a study on whether they boost performance.
Perimenopause and postmenopause bring hormonal shifts that can complicate weight management, and many obesity drug trials do not break out results by menopausal stage at all. The new orforglipron data did, and the pill's weight loss effect stayed consistent whether a participant was in perimenopause, postmenopause, or neither. That consistency matters for women who have wondered whether hormonal changes would blunt the drug's effect on them specifically. Orforglipron, sold as Foundayo since its FDA approval in April, kept its weight loss effect across menopausal stages, and this kind of subgroup detail can shape how doctors talk about it with patients going through midlife hormonal changes.
This kind of interaction has not drawn much attention until now, since most guidance around GLP-1 medications focuses on food and alcohol rather than other substances. A doctor is now flagging cannabis specifically, pointing out that combining it with a GLP-1 drug could carry effects that patients and even some prescribers have not fully considered. Anyone using both should raise the topic directly with whoever manages their prescription, since general guidance cannot substitute for a conversation about a specific combination of medications and habits. It is a reminder that the list of things worth mentioning to a doctor keeps growing as these drugs reach wider use.
Earlier this week, on September 24, the FDA approved Lilly's once-weekly insulin Onswik, giving patients another option for less frequent dosing, and Lilly's stock climbed toward the $1,200 mark. That puts two pieces of good news for the company in the same week, one about a pill already on the market and one about a product newly cleared for use. Together they point to a company expanding on multiple fronts at once, from oral obesity treatment to insulin delivery.
VK2735, Viking Therapeutics' drug candidate in the same GLP-1 category, posted trial numbers strong enough to draw real attention this week. But the source reporting on those results added a note of caution, urging readers not to read too much into early results before more data comes in. That caution is a fair one, since early trial results can look strong and still fail to hold up as a program moves through later stages. Readers tracking Viking as a competitor in this market should watch for follow up data before drawing firm conclusions.
Sports regulators do not typically weigh in on diabetes or weight loss medications, which makes this development notable. WADA, which has monitored GLP-1s since 2024, declined to ban them this month and is funding a study on whether they boost performance. That attention signals something beyond the medications' original purpose in weight loss and diabetes care, since these drugs have moved into a wider set of uses and users. The study's results will shape whether the rules change, but the fact that regulators are watching at all says something about how far these medications have moved beyond their original use. It is one more sign that GLP-1 drugs are no longer confined to the clinical settings where they started.
Two things stand out for readers making decisions based on today's news. First, if you are in perimenopause or postmenopause and considering orforglipron, this data offers a more complete picture of what to expect than most trials provide. Second, if you use cannabis alongside a GLP-1 prescription, raise it directly with your doctor rather than assuming it will not matter. The rest of today's news, from Lilly's insulin approval to WADA's study of GLP-1s in sport, is worth watching as it develops, but none of it should change a treatment decision on its own without talking to your prescriber first.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.